462 related articles for article (PubMed ID: 11309281)
1. Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention.
Williams JL; Borgo S; Hasan I; Castillo E; Traganos F; Rigas B
Cancer Res; 2001 Apr; 61(8):3285-9. PubMed ID: 11309281
[TBL] [Abstract][Full Text] [Related]
2. NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property?
Yeh RK; Chen J; Williams JL; Baluch M; Hundley TR; Rosenbaum RE; Kalala S; Traganos F; Benardini F; del Soldato P; Kashfi K; Rigas B
Biochem Pharmacol; 2004 Jun; 67(12):2197-205. PubMed ID: 15163551
[TBL] [Abstract][Full Text] [Related]
3. Phosphatidylcholine-associated nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit DNA synthesis and the growth of colon cancer cells in vitro.
Dial EJ; Doyen JR; Lichtenberger LM
Cancer Chemother Pharmacol; 2006 Feb; 57(3):295-300. PubMed ID: 16032431
[TBL] [Abstract][Full Text] [Related]
4. Superior effectiveness of ibuprofen compared with other NSAIDs for reducing the survival of human prostate cancer cells.
Andrews J; Djakiew D; Krygier S; Andrews P
Cancer Chemother Pharmacol; 2002 Oct; 50(4):277-84. PubMed ID: 12357301
[TBL] [Abstract][Full Text] [Related]
5. NCX 4016, a nitric oxide-releasing aspirin derivative, exhibits a significant antiproliferative effect and alters cell cycle progression in human colon adenocarcinoma cell lines.
Tesei A; Ricotti L; Ulivi P; Medri L; Amadori D; Zoli W
Int J Oncol; 2003 Jun; 22(6):1297-302. PubMed ID: 12738997
[TBL] [Abstract][Full Text] [Related]
6. Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: implications for chemoprevention.
Williams JL; Nath N; Chen J; Hundley TR; Gao J; Kopelovich L; Kashfi K; Rigas B
Cancer Res; 2003 Nov; 63(22):7613-8. PubMed ID: 14633677
[TBL] [Abstract][Full Text] [Related]
7. Molecular targets of nitric-oxide-donating aspirin in cancer.
Kashfi K; Rigas B
Biochem Soc Trans; 2005 Aug; 33(Pt 4):701-4. PubMed ID: 16042578
[TBL] [Abstract][Full Text] [Related]
8. TNF-related apoptosis-inducing ligand cooperates with NSAIDs via activated Wnt signalling in (pre)malignant colon cells.
Heijink DM; Jalving M; Oosterhuis D; Sloots IA; Koster R; Hollema H; Kleibeuker JH; Koornstra JJ; de Vries EG; de Jong S
J Pathol; 2011 Feb; 223(3):378-89. PubMed ID: 21171083
[TBL] [Abstract][Full Text] [Related]
9. Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: a general property and evidence of a tissue type-independent effect.
Chattopadhyay M; Kodela R; Nath N; Dastagirzada YM; Velázquez-Martínez CA; Boring D; Kashfi K
Biochem Pharmacol; 2012 Mar; 83(6):715-22. PubMed ID: 22222427
[TBL] [Abstract][Full Text] [Related]
10. Nitric-oxide-donating NSAIDs as agents for cancer prevention.
Rigas B; Kashfi K
Trends Mol Med; 2004 Jul; 10(7):324-30. PubMed ID: 15242680
[TBL] [Abstract][Full Text] [Related]
11. Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect.
Kashfi K; Rayyan Y; Qiao LL; Williams JL; Chen J; Del Soldato P; Traganos F; Rigas B; Ryann Y
J Pharmacol Exp Ther; 2002 Dec; 303(3):1273-82. PubMed ID: 12438552
[TBL] [Abstract][Full Text] [Related]
12. NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin.
Konturek PC; Kania J; Burnat G; Hahn EG
J Physiol Pharmacol; 2006 Dec; 57 Suppl 12():15-24. PubMed ID: 17244951
[TBL] [Abstract][Full Text] [Related]
13. Antiproliferative effects of nitrosulindac on human colon adenocarcinoma cell lines.
Lavagna C; Burgaud JL; Del Soldato P; Rampal P
Biochem Biophys Res Commun; 2001 Jun; 284(3):808-16. PubMed ID: 11396974
[TBL] [Abstract][Full Text] [Related]
14. Novel agents for cancer prevention based on nitric oxide.
Rigas B
Biochem Soc Trans; 2007 Nov; 35(Pt 5):1364-8. PubMed ID: 17956352
[TBL] [Abstract][Full Text] [Related]
15. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model.
Chattopadhyay M; Kodela R; Olson KR; Kashfi K
Biochem Biophys Res Commun; 2012 Mar; 419(3):523-8. PubMed ID: 22366248
[TBL] [Abstract][Full Text] [Related]
16. Development of novel agents based on nitric oxide for the control of colon cancer.
Kozoni V; Rosenberg T; Rigas B
Acta Pharmacol Sin; 2007 Sep; 28(9):1429-33. PubMed ID: 17723176
[TBL] [Abstract][Full Text] [Related]
17. Expression profile analysis of colon cancer cells in response to sulindac or aspirin.
Iizaka M; Furukawa Y; Tsunoda T; Akashi H; Ogawa M; Nakamura Y
Biochem Biophys Res Commun; 2002 Mar; 292(2):498-512. PubMed ID: 11906190
[TBL] [Abstract][Full Text] [Related]
18. [Inhibition of vascular smooth muscle cell proliferation by non-steroidal anti-inflammatory drugs].
Wang YQ; Brooks G; Harper J; Li YQ; Zhu CB; Yuan WZ; Wu XS
Shi Yan Sheng Wu Xue Bao; 2003 Apr; 36(2):85-90. PubMed ID: 12858504
[TBL] [Abstract][Full Text] [Related]
19. Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis.
Shiff SJ; Koutsos MI; Qiao L; Rigas B
Exp Cell Res; 1996 Jan; 222(1):179-88. PubMed ID: 8549662
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro.
Andrews P; Zhao X; Allen J; Li F; Chang M
Cancer Chemother Pharmacol; 2008 Feb; 61(2):203-14. PubMed ID: 17447067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
